Published in MedGenMed on January 14, 2004
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
The DNA damage response: putting checkpoints in perspective. Nature (2000) 19.07
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med (1999) 7.81
Guidelines for healthy weight. N Engl J Med (1999) 7.03
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med (2002) 6.19
Clinical practice. Mammographic screening for breast cancer. N Engl J Med (2003) 6.01
Physical activity and the risk of breast cancer. N Engl J Med (1997) 5.85
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med (1996) 5.14
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA (2003) 4.72
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer (1994) 4.37
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med (1997) 4.33
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
Assessing the risk of breast cancer. N Engl J Med (2000) 3.72
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med (2003) 3.46
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA (2000) 3.15
Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst (1995) 3.03
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet (2003) 2.24
Roads leading to breast cancer. N Engl J Med (2000) 2.18
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 2.11
Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst (2001) 1.85
Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. JAMA (2001) 1.76
Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol (2002) 1.68
Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet C Semin Med Genet (2003) 1.36
Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J (2002) 1.11
Breast cancer risk assessment models: applicability to African-American women. Cancer (2003) 1.09
Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev (2001) 1.07
Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing. Int J Technol Assess Health Care (2003) 0.98
Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer (1996) 0.96
Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol (1993) 0.96
Evidence for the presence of mutagenic arylamines in human breast milk and DNA adducts in exfoliated breast ductal epithelial cells. Environ Mol Mutagen (2002) 0.94
Age at any birth is associated with breast cancer risk. Epidemiology (2001) 0.92
Risk analysis and risk management in an uncertain world. Risk Anal (2002) 0.91
Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst (2002) 0.90
DNA repair proficiency: a potential marker for identification of high risk members in breast cancer families. Cancer Lett (1998) 0.89
Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med (2002) 0.88
Risk of breast and ovarian cancer in women with strong family histories. Oncology (Williston Park) (2001) 0.86
Familial effects of prostate and other cancers on lifetime breast cancer risk. Breast Cancer Res Treat (1993) 0.85
The assessment of genetic risk of breast cancer: a set of GP guidelines. Fam Pract (1999) 0.83
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res (2003) 0.83
Risk estimation for breast cancer development; a clinical perspective. Surg Oncol (2002) 0.82
The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography? Eur J Cancer (2001) 0.80
Acceptability of prophylactic mastectomy in cancer-prone women. JAMA (2000) 0.79
Roads to breast cancer. N Engl J Med (2001) 0.79
Is mammography indicated for women with defective BRCA genes? Implications of recent scientific advances for the diagnosis, treatment, and prevention of hereditary breast cancer. MedGenMed (2000) 0.79
Genetic testing for breast and ovarian cancer for women with a family history of breast cancer: weighing conflicting evidence about oral contraceptives. MedGenMed (2002) 0.79
Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine. Oncology (Williston Park) (2002) 0.78
Management of the high-risk patient. Surg Clin North Am (2003) 0.78
BRCA1: an emerging role in the cellular response to DNA damage. Lancet (2000) 0.77
For patients, prediction of cancer risk can be worrisome. J Natl Cancer Inst (2003) 0.76
A current perspective on genetic testing for breast and ovarian cancer: the oral contraceptive decision. MedGenMed (2001) 0.76
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 0.76